It is also unclear whether other variables such as conditioning intensity, graft‐versus‐host disease (GVHD) prophylaxis strategy, or donor selection has any impact on the posttransplant outcomes of patients with TP53 mutant AML. Here, TP53 is linked to acute myeloid leukemia.